Group 1 - The core point of the article is that Yiling Pharmaceutical (002603.SZ) has forecasted a significant turnaround in its financial performance for 2025, expecting a net profit of between 1.2 billion to 1.3 billion yuan, compared to a loss of approximately 725 million yuan in 2024, indicating a successful recovery and substantial profit growth [1] - Yiling Pharmaceutical's wholly-owned subsidiary, Yiling Wanzhou International Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its first independently developed chemical drug, Manshuan (Phenylacetone Injection), marking a significant milestone for the company [1][3] - The approval of Phenylacetone Injection provides a new treatment option for postoperative pain management, particularly in abdominal and thoracoscopic surgeries, aligning with the guidelines from the Chinese Medical Association [3][4] Group 2 - According to the National Bureau of Statistics, there were 312 million inpatient admissions and 104 million surgical procedures in China's medical institutions in 2024, reflecting an 8% year-on-year increase from 2023, indicating a growing market for postoperative pain management solutions [4] - In the first three quarters of 2025, Yiling Pharmaceutical achieved operating revenue of 5.868 billion yuan, with net profit exceeding 1 billion yuan, representing a year-on-year increase of 80.33%, and a 90.53% increase in net profit after excluding non-recurring gains and losses [4] - The company emphasizes that 2025 is a critical year for its "13th Five-Year Plan," focusing on long-term development amidst market complexities, enhancing management, expanding market reach, and implementing a comprehensive cost control system to improve profit margins [4]

Core Viewpoint - Yiling Pharmaceutical's subsidiary, Yiling Wanzhou International Pharmaceutical, has received approval from the National Medical Products Administration for the marketing authorization of Anilofin Injection (brand name: Wanshuan), which is a patented chemical drug for postoperative analgesia [1] Group 1: Product Approval - The injection is a new chemical drug indicated for postoperative pain relief [1] - The approval provides a new option for clinical postoperative analgesia, enriching the company's chemical drug pipeline [1] Group 2: Market Context - In 2024, the number of surgical procedures in China is projected to reach 104 million, representing an 8% year-on-year increase [1] - The drug's sales and production may be influenced by market policies and other factors [1]